5.24
price up icon0.58%   0.03
after-market Dopo l'orario di chiusura: 5.19 -0.05 -0.95%
loading
Precedente Chiudi:
$5.21
Aprire:
$5.21
Volume 24 ore:
540.85K
Relative Volume:
0.56
Capitalizzazione di mercato:
$1.87B
Reddito:
$563.46M
Utile/perdita netta:
$27.92M
Rapporto P/E:
54.36
EPS:
0.0964
Flusso di cassa netto:
$-146.33M
1 W Prestazione:
-2.60%
1M Prestazione:
+38.99%
6M Prestazione:
+35.05%
1 anno Prestazione:
-34.74%
Intervallo 1D:
Value
$5.14
$5.34
Intervallo di 1 settimana:
Value
$5.06
$5.40
Portata 52W:
Value
$2.94
$9.25

Alvotech Stock (ALVO) Company Profile

Name
Nome
Alvotech
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
1,460
Name
Cinguettio
Name
Prossima data di guadagno
2026-08-19
Name
Ultimi documenti SEC
Name
ALVO's Discussions on Twitter

Compare ALVO vs TAK, TEVA, HLN, ZTS, UTHR

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
ALVO icon
ALVO
Alvotech
5.24 1.86B 563.46M 27.92M -146.33M 0.0964
TAK icon
TAK
Takeda Pharmaceutical Co Adr
18.11 58.15B 29.91B 1.30B 3.49B 0.4056
TEVA icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
36.35 42.94B 17.53B 1.58B 444.18M 1.3457
HLN icon
HLN
Haleon Plc Adr
9.22 40.59B 14.54B 2.22B 2.58B 0.4871
ZTS icon
ZTS
Zoetis Inc
72.86 30.29B 9.51B 2.64B 2.14B 6.0361
UTHR icon
UTHR
United Therapeutics Corp
503.86 21.74B 3.17B 1.29B 1.01B 27.09

Alvotech Stock (ALVO) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-12-09 Iniziato Barclays Underweight
2025-11-04 Downgrade Deutsche Bank Buy → Hold
2025-10-14 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2025-09-23 Aggiornamento Deutsche Bank Hold → Buy
2025-02-14 Iniziato UBS Buy
2024-01-29 Aggiornamento Barclays Equal Weight → Overweight
2023-10-20 Aggiornamento Citigroup Sell → Neutral
2023-09-21 Iniziato Barclays Equal Weight
2022-09-07 Iniziato Morgan Stanley Equal-Weight
2022-09-06 Downgrade Citigroup Buy → Sell
2022-07-26 Iniziato Citigroup Buy
Mostra tutto

Alvotech Borsa (ALVO) Ultime notizie

pulisher
Sep 08, 2026

What Is Putting Alvotech Stock in Focus? (NASDAQ:ALVO) - Kalkine Media

Sep 08, 2026
pulisher
Sep 08, 2026

Citadel Advisors LLC Makes New $6.38 Million Investment in Alvotech $ALVO - marketbeat.com

Sep 08, 2026
pulisher
Sep 08, 2026

Understanding the Setup: (ALVO) and Scalable Risk - Stock Traders Daily

Sep 08, 2026
pulisher
Sep 07, 2026

Alvotech (ALVO) Is Up 7.5% After FDA Accepts Review Of Key Entyvio Biosimilar AVT80 - simplywall.st

Sep 07, 2026
pulisher
Sep 02, 2026

Alvotech and Lotus Enter Agreement for Durvalumab and Emicizumab Biosimilars - marketscreener.com

Sep 02, 2026
pulisher
Aug 31, 2026

Alvotech’s Subcutaneous Biosimilar Vedolizumab BLA Accepted for Review by FDA - Pearce IP

Aug 31, 2026
pulisher
Aug 31, 2026

Alvotech (NASDAQ:ALVO) Shares Up 5.4%Here's What Happened - marketbeat.com

Aug 31, 2026
pulisher
Aug 31, 2026

FDA to review Alvotech (Nasdaq: ALVO) subcutaneous Entyvio biosimilar - stocktitan.net

Aug 31, 2026
pulisher
Aug 31, 2026

Alvotech Says FDA Accepted Biologics License Application for AVT80 - marketscreener.com

Aug 31, 2026
pulisher
Aug 31, 2026

Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous Presentations - Yahoo Finance

Aug 31, 2026
pulisher
Aug 30, 2026

Alvotech (ALVO) Is Up 11.7% After Lotus Biosimilar Licensing Deal and 2026 Guidance Update – Has The Bull Case Changed? - simplywall.st

Aug 30, 2026
pulisher
Aug 29, 2026

Why Alvotech (ALVO) Is Up 11.7% After Expanding Biosimilar Deal With Lotus Pharmaceutical - Yahoo Finance

Aug 29, 2026
pulisher
Aug 28, 2026

Alvotech (ALVO) Stock Still Trades At A Discount After A 57% Rally - simplywall.st

Aug 28, 2026
pulisher
Aug 27, 2026

Alvotech to present at upcoming investor conferences in September - finance.yahoo.com

Aug 27, 2026
pulisher
Aug 26, 2026

Alvotech (ALVO) On FDA Clearance And Lotus Deal As Undervalued Narrative Gains Ground - simplywall.st

Aug 26, 2026
pulisher
Aug 24, 2026

BofA starts bullish Alvotech coverage on biosimilar launch cycle - Investing.com

Aug 24, 2026
pulisher
Aug 23, 2026

Why Alvotech (ALVO) Is Up 9.2% After $150 Million Lotus Biosimilar Deal And 2026 Update - Sahm

Aug 23, 2026
pulisher
Aug 22, 2026

ALVOTECH ($ALVO) Releases Q2 2026 Earnings - Moomoo

Aug 22, 2026
pulisher
Aug 22, 2026

Alvotech licenses durvalumab and emicizumab biosimilar candidates to Lotus in ~$150M deal - Dealroom

Aug 22, 2026
pulisher
Aug 22, 2026

Alvotech Targets Three U.S. Biosimilar Decisions In Q4 After FDA Manufacturing Inspection Closes - pulse2.com

Aug 22, 2026
pulisher
Aug 22, 2026

Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Alvotech (ALVO) and Abbott Laboratories (ABT) - The Globe and Mail

Aug 22, 2026
pulisher
Aug 21, 2026

Teleconferência de Resultados do 2T26 da Alvotech (ALVO): Guidance Reafirmado - TradingKey

Aug 21, 2026
pulisher
Aug 21, 2026

Alvotech (NASDAQ:ALVO) Builds Momentum Around Biosimilar Expansion - Kalkine Media

Aug 21, 2026
pulisher
Aug 21, 2026

Alvotech 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ALVO) 2026-08-21 - Seeking Alpha

Aug 21, 2026
pulisher
Aug 21, 2026

Alvotech, Lotus Ink Biosimilar Licensing and Commercialization Pact in US, Asia - Contract Pharma

Aug 21, 2026
pulisher
Aug 21, 2026

Alvotech (NASDAQ:ALVO) Sees Strong Trading VolumeWhat's Next? - MarketBeat

Aug 21, 2026
pulisher
Aug 21, 2026

Alvotech licenses two early-stage biosimilar candidates to Lotus for USD 150m - AllSci

Aug 21, 2026
pulisher
Aug 21, 2026

Alvotech (NASDAQ: ALVO) bets on U.S. biosimilars with Lotus - Stock Titan

Aug 21, 2026
pulisher
Aug 21, 2026

Alvotech Enters Licensing, Commercialization Deal for Two Biosimilars in US, Certain Asian Markets - marketscreener.com

Aug 21, 2026
pulisher
Aug 21, 2026

Alvotech Enters Strategic Licensing and Commercialization Agreement with Lotus Pharmaceutical for AVT34 and AVT87 - Quiver Quantitative

Aug 21, 2026
pulisher
Aug 21, 2026

Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for ... - Enidnews.com

Aug 21, 2026
pulisher
Aug 21, 2026

Alvotech and Lotus sign deal for proposed versions of $6.1B and $5.8B medicines - Stock Titan

Aug 21, 2026
pulisher
Aug 21, 2026

Alvotech Q2 2026 Earnings Call Transcript - Sahm

Aug 21, 2026
pulisher
Aug 20, 2026

Alvotech (ALVO) Stock Rises On Guidance Resolve Despite Lingering Loss Risk - simplywall.st

Aug 20, 2026
pulisher
Aug 20, 2026

Alvotech Files H1 2026 Results and Schedules Business Update Call - The Globe and Mail

Aug 20, 2026
pulisher
Aug 20, 2026

Alvotech holds rating despite H1 2026 earnings miss and FDA delays, eyes multiple biosimilar approvals by Q4 2026. - Pluang

Aug 20, 2026
pulisher
Aug 20, 2026

Alvotech earnings missed by $0.02, revenue fell short of estimates - Investing.com India

Aug 20, 2026
pulisher
Aug 20, 2026

Alvotech: Reiterate Hold On AVT05/AVT06 BLA Resubmissions And Upcoming Catalysts (ALVO) - Seeking Alpha

Aug 20, 2026
pulisher
Aug 20, 2026

Alvotech (NASDAQ:ALVO) Trading 6.8% HigherHere's What Happened - MarketBeat

Aug 20, 2026
pulisher
Aug 20, 2026

Alvotech Q2 Earnings Call Highlights - MarketBeat

Aug 20, 2026
pulisher
Aug 20, 2026

Earnings call transcript: Alvotech misses Q2 2026 estimates as revenue stalls - Investing.com

Aug 20, 2026
pulisher
Aug 20, 2026

ALVO: Revenue and margins set to rebound in H2 as supply normalizes and portfolio expands - TradingView

Aug 20, 2026
pulisher
Aug 20, 2026

Alvotech Q2 2026 Earnings Call Summary - Yahoo Finance

Aug 20, 2026
pulisher
Aug 20, 2026

Alvotech Provides Earnings Guidance for the Full Year 2026 - marketscreener.com

Aug 20, 2026
pulisher
Aug 20, 2026

Alvotech 1H Adjusted EBITDA $46.9 M >ALVO - Moomoo

Aug 20, 2026
pulisher
Aug 20, 2026

Alvotech (ALVO) reports Q2 loss, beats revenue estimates - FXStreet

Aug 20, 2026
pulisher
Aug 19, 2026

Alvotech (ALVO) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance

Aug 19, 2026
pulisher
Aug 19, 2026

Iceland's Alvotech H1 revenue falls 31% on manufacturing program - TradingView

Aug 19, 2026
pulisher
Aug 19, 2026

Alvotech (NASDAQ:ALVO) Releases Earnings Results, Misses Estimates By $0.17 EPS - MarketBeat

Aug 19, 2026
pulisher
Aug 19, 2026

Alvotech Q2 Results: EPS Misses Estimate, Sales Fall 39% YoY - scanx.trade

Aug 19, 2026
pulisher
Aug 19, 2026

Alvotech H1 Results: Revenue falls 31%, EBITDA down 13% - scanx.trade

Aug 19, 2026

Alvotech Azioni (ALVO) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$46.11
price up icon 1.56%
RDY RDY
$11.71
price down icon 1.43%
$22.86
price down icon 2.93%
$156.57
price up icon 0.92%
$16.38
price down icon 0.73%
$503.86
price down icon 0.58%
Capitalizzazione:     |  Volume (24 ore):